Language selection

Search

Biomanufacturing: Advancing health sciences industry in Canada

From: Innovation, Science and Economic Development Canada

Biomanufacturing in Canada

Ensuring access to critical vaccines, therapeutics and other health products is a priority for the Government of Canada. At the outset of the COVID-19 pandemic, the Government of Canada took early and decisive action to strengthen Canada's biomanufacturing capacity to protect Canadians. We continue to invest in domestic biomanufacturing capabilities and secure medical countermeasures.

Biomanufacturing projects underway

Find out about current biomanufacturing projects in Canada

Biomanufacturing video series: Launch video

Minister Champagne introduces how the Government of Canada is bringing Canadian biomanufacturing to life, protecting Canadians for the longer-term

Biomanufacturing ecosystem
Find out why domestic biomanufacturing is important for Canada
Biomanufacturing infrastructure
Learn more about the Biologics Manufacturing Centre
Public consultation
The stakeholder consultation closed March 12, 2021. Watch this space for updates on what we heard

Advancing the health sciences industry

Since March 2020, the government has taken a multifaceted approach including over $1 billion in advance purchase agreements to secure a domestic supply of up to 429 million doses of promising COVID-19 vaccines. The Government of Canada has also committed $792 million through the Strategic Innovation Fund (SIF), to support research and development, clinical trials, and the manufacturing of vaccines and therapeutic drugs to fight COVID-19.

Innovation, Science, and Economic Development Canada – in partnership with Health Canada, the Public Health Agency of Canada, and partner departments and agencies – is actively engaging with stakeholders. This engagement is to explore ways that the Government of Canada can support future pandemic preparedness, including through vaccine and therapeutic manufacturing in Canada.

COVID-19 health product industry
Information for health product manufacturers and distributors in relation to COVID-19

Microbial fermentation pilot plant
See how the NRC helps its collaborators optimize and scale up production processes

Cell culture pilot plant
See how the NRC helps its collaborators scale up cell culture processes


Related links:


Contact

General inquiries

Do you have questions? Contact us

Media Relations

Innovation, Science and Economic Development Canada
Telephone: 343-291-1777
Email: ic.mediarelations-mediasrelations.ic@canada.ca

Did you find what you were looking for?

What was wrong?

You will not receive a reply. Telephone numbers and email addresses will be removed.
Maximum 300 characters

Thank you for your feedback

Date modified: